Intravenous Thyroxine Administration in Hospitalized Patients, a Common but Unreported Practice: a Single Institution Recent Experience

Background: Intravenous levothyroxine (IVT4) is FDA-approved for the treatment of myxedema coma (ME). ATA guidelines also acknowledge other rare situations, mostly such where oral/enteral access is compromised for prolonged periods, in which IVT4 may be appropriate. We noticed that at our hospital,...

Descripción completa

Detalles Bibliográficos
Autores principales: Tordjman, Karen Michele, Bishouty, Nancy, Mendel, Liran, Erhnwald, Michal, Najjar, Mahmoud, Daoud, Inas Abu, Greenman, Yona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Thyroid
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8090342/
http://dx.doi.org/10.1210/jendso/bvab048.1695

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8090342/
http://dx.doi.org/10.1210/jendso/bvab048.1695

Ejemplares similares